9ª Edição

TheraP study shows promising results with radioligand 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer

per: Grupo Oncoclínicas
TheraP study shows promising results with radioligand 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer

Scientific commission

André Fay
André Fay
Carlos Augusto Vasconcelos
Carlos Augusto Vasconcelos
Diogo Rosa
Diogo Rosa
Luiz Flávio Coutinho
Luiz Flávio Coutinho

Contributors

Marcel Tolentino de Rezende
Marcel Tolentino de Rezende
Nicole Machado Rossi Monteiro
Nicole Machado Rossi Monteiro

The radioligand 177Lu-PSMA-617 showed significant results in patients with metastatic castration-resistant prostate cancer (mCRPC). According to Marcel Tolentino de Rezende, an oncologist at Oncocentro Belo Horizonte, a clinic of the Oncoclínicas Group in Minas Gerais, the drug is a small molecule targeted to the prostate-specific membrane antigen (PSMA) linked to a radiation-emitting radionuclide (lutetium 177). beta that showed activity in a phase 2 study: “Therefore, it is a personalized target drug”, he says.

In a study that included 200 men with this neoplasm profile and already treated with docetaxel, LuPSMA showed promise as an alternative therapy to cabazitaxel, with significantly greater activity. After disease progression with docetaxel, PSMA-targeted radionuclide therapy reduced the risk of disease progression or death by 37%. In the present study, patients treated with PSMA-617 (LuPSMA), labeled with lutetium-177, had lower toxicity and better quality of life compared to those who received cabazitaxel.

For Nicole Machado Rossi Monteiro, an oncologist at the Nucleus of Hematology and Oncology, clinic of Grupo Oncoclínicas in Minas Gerais, the fact that more than 80% of prostate cancer tumors highly express the phenotypic biomarker PSMA makes it a promising therapeutic target. for radioligand therapy.

Go to our website and read the full article, with all the details of the TheraP study.

Access the full article of this study
Download
Share
Or share the link
Link copied to your desktop.L